Thus, in the present study, the survival significance of patients with low PSA level, but with high GS for prostate cancer after RP, EBRT, or EBRT plus BT, was assessed for future guidance on the treatment of these kind of patients in clinic. This evidence concerns the gene KLK3 and prostate carcinoma.